Castle Hill Medical Centre

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• High blood pressure3 trials
• Type 2 diabetes3 trials
• Obesity2 trials
• Chronic kidney disease1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Active, not recruiting2 trials
• Not yet recruiting2 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• Novo Nordisk A/S4 trials
• Mineralys Therapeutics Inc.2 trials

Running trials

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

  NCT07931573· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07668388· Phase 2· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source